BACKGROUND: Inflammatory breast carcinoma (IBC) is a rare and aggressive malignancy. Therapy for patients with IBC is multidisciplinary, and response to preoperative chemotherapy is considered an important predictor of outcome. Although only a limited number of molecular markers have been investigated in this setting, none has exhibited prognostic value for patients with IBC. METHODS: Immunohistochemical assays for P53, MDM-2, and MUC-1 were performed retrospectively to evaluate potential correlations between these markers and pathologic response, time to progression (TTP), and overall survival (OS) in 19 patients with IBC. RESULTS: After a median follow-up period of 46 months, patients with tumors that overexpressed P53 and did not express MUC-1 had a significantly shorter median TTP and median OS compared with other patients. CONCLUSIONS: Expression of P53 and MUC-1 may be predictive of treatment efficacy and outcome for patients with IBC. Furthermore, these two markers may represent novel therapeutic targets in such patients. Copyright 2004 American Cancer Society.
BACKGROUND:Inflammatory breast carcinoma (IBC) is a rare and aggressive malignancy. Therapy for patients with IBC is multidisciplinary, and response to preoperative chemotherapy is considered an important predictor of outcome. Although only a limited number of molecular markers have been investigated in this setting, none has exhibited prognostic value for patients with IBC. METHODS: Immunohistochemical assays for P53, MDM-2, and MUC-1 were performed retrospectively to evaluate potential correlations between these markers and pathologic response, time to progression (TTP), and overall survival (OS) in 19 patients with IBC. RESULTS: After a median follow-up period of 46 months, patients with tumors that overexpressed P53 and did not express MUC-1 had a significantly shorter median TTP and median OS compared with other patients. CONCLUSIONS: Expression of P53 and MUC-1 may be predictive of treatment efficacy and outcome for patients with IBC. Furthermore, these two markers may represent novel therapeutic targets in such patients. Copyright 2004 American Cancer Society.
Authors: Shaheenah Dawood; Kristine Broglio; Yun Gong; Wei-Tse Yang; Massimo Cristofanilli; Shu-Wan Kau; Funda Meric-Bernstam; Thomas A Buchholz; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: Cancer Date: 2008-05-01 Impact factor: 6.860
Authors: Michal Mego; Antonio Giordano; Ugo De Giorgi; Hiroko Masuda; Limin Hsu; Mario Giuliano; Tamer M Fouad; Shaheenah Dawood; Naoto T Ueno; Vicente Valero; Eleni Andreopoulou; Ricardo H Alvarez; Wendy A Woodward; Gabriel N Hortobagyi; Massimo Cristofanilli; James M Reuben Journal: Breast Cancer Res Date: 2015-01-09 Impact factor: 6.466